Research team finds a vaccine candidate that stimulates the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains.
17 December 2014 | Fred Hutchinson Cancer Research Center press release
A non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3-D structure could fight and even help prevent cancer and also infectious disease such as HIV, scientists have demonstrated. Tiny biodegradable rod-like structures made from silica, known as mesoporous silica rods (MSRs), can be loaded with biological and chemical drug components and then delivered by needle just underneath the skin, they explain.
10 December 2014 | Science Daily
A new vaccine developed by researchers at the University of Oxford has generated a strong immune response against the Hepatitis C virus in human volunteers. The vaccine is the first Hepatitis C inoculation to reach this stage of clinical trials, and the results have been promising. The 15 healthy human volunteers who took part in the phase 1 safety trial all responded positively.The study found that after the second, booster inoculation, all 15 volunteers had large, broad and sustained T cells responses.
26 November 2014 | Cherwell
In the US, routine administration of quadrivalent HPV vaccine is recommended for girls and boys at 11-12 yrs, with catch-up vaccination recommended up to 26 yrs for girls, and 21 yrs for boys. The difficulty has been in the implementation of the recommendation: overall rates of initiating and completion among US teenage girls currently stand at 57% and 35% respectively.
11 November 2014 | BMJ
At this first international meeting to bring researchers from all biomedical HIV prevention approaches together under one roof, neither the time and disappointments leading up to this point, or the uncertainty of how much more time lies ahead, did anything to dampen a sense of optimism and ambition that AVAC director Mitchell Warren sums up as “momentum.”
05 November 2014 | Science Speaks
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus. The study, published online today in Nature, reveals that the building blocks of the immature form of HIV are arranged in a surprising way.
04 November 2014 | Medical Xpress
The only HIV vaccine in the world that worked slightly in Thailand also seems to work on South Africans.
30 October 2014 | AllAfrica
New research that sheds light on the methods and machinery used by HIV to infect cells provides insight into the tricky virus that potentially could guide the development of a vaccine against the virus that causes AIDS, according to U.S. government and other scientists.
09 October 2014 | Reuters
In the most brazen case of medical research fraud since the 1974 "patchwork mouse" scandal, scientist Dong-Pyou Han has admitted to faking an HIV vaccine experiment to gain federal funding.
24 September 2014 | Healthline
Like others before him, Jean-Marie Andrieu believes he may have hit upon the long sought after HIV vaccine. And like numerous other treatments under development, the hitch is that the vaccine has only thus far only shown to be effective in protecting monkeys against the Simian Immunodeficiency Virus or SIV, the monkey equivalent to HIV.
11 September 2014 | Washington Post (blog)